

August 09, 2016

The Manager-Listing Department, Bombay Stock Exchange Limited Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai – 400 001.

BSE Scrip Code No.524280

The Manager-Listing Department, The National Stock Exchange of India Limited, Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai 400 051

NSE Symbol: KOPRAN

Sub: Unaudited Standalone and Consolidated Financial Results for the 1st quarter ended 30th June, 2016.

Dear Sir/Madam,

Pursuant to Clause 33 read with Clause 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting the Board approved Unaudited Standalone and Consolidated Financial Results for the first quarter ended 30th June, 2016 along with Limited Review Report.

Kindly publish the results on your websites.

The Meeting of the Board of Directors of the Company commenced at 3.00 PM and concluded at ... 4.45 PM

Regards,

For Kopran Limited

Sunil Sodhani Company Secretary

Encl: As above.



	HINALIDITED		GETABLED	ENDED 30TH	IIINE 2018			
Part-		NESOFI S	NE CONTRACTOR OF THE CONTRACTO		2025		(Rupe	(Rupees in lakhs)
		Stan	Standalone			Consolidated	dated	
Particulars		Quarter ended	p	Year ended		Quarter ended		Year ended
	30-06-2016	31/03/2016	30/06/2015	31/03/2016	30-06-2016	31/03/2016	30/06/2015	31/03/2016
	Unaudited	Unaudited '	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Audited
(1) Income from Operations	0000	7007	000	40.400	4	7 534	700 0	20 00
(a) Net Sales/Income from Operations (Net of Excise Duty)  (b) Other Operating Income	3,039	4,224	4,238 132	16,100	164	223	168	806
Total Income from operations (net)	3,149	4,398	4,391	18,732	6,129	7,754	6,262	29,632
(2) Expenses			<u> </u>					
(a) Cost of Materials consumed	1,577	1,841	1,915	8,625	3,589	5,998	3,133	17,855
(b) Purchase of stock-in-trade	516	440	928	2,830	323	(1,834)	926	289
(c) Changes in Inventories of finished goods, work-in-progress & stock-in-trade	(73)	188	(43)	(16)	(117)	297	(270)	(118)
(d) Employee benefits expense	381	349	392	1,605	681	644	069	2,803
(e) Depreciation and amortisation expense	8	78	75	314	204	204	198	812
(f) Other expenses	663	915	269	3,255	1,229	1,521	1,271	5,781
Total Expenses	3,145	3,811	3,964	16,553	5,909	6,830	5,948	27,422
(3) Profit (Loss) from operations before other income, finance cost & exceptional items	4	587	427	2,179	220	924	314	2,210
(4) Other Income	248	9	62	83	267	50	35	237
(5) Profit / (Loss) from ordinary activities before finance costs & exceptional items	252	593	489	2,262	487	974	349	2,447
	181	282	233	666	277	340	290	1,256
(7) Profit / (Loss) from ordinary activities before exceptional items	71	311	256	1,263	210	634	59	1,191
(8) Exceptional items (Net)		(122)	2	(119)	•	(121)	2	(119)
(9) Profit / (Loss) from ordinary activities before tax	71	189	258	1,144	210	513	61	1,072
(10) Tax Expenses	-	•	'		ι	•		
(11) Net Profit / (Loss) from ordinary activities after tax	71	189	258	1,144	210	513	61	1,072
(12) Paid up equity share Capital (Face value Rs 10/-)	4,325	4,325	4,110	4,325	4,325	4,325	4,110	4,325
(13) Reserves excluding Revaluation Reserve as per balance sheet of previous accounting yea	•	•	•	14,482				5,711
(14) Earning Per Share (EPS) Before Exceptional Item	•	1	ć	Ċ	9		, 1	88 6
(a) Basic	0.16	0.73	0.63	3.05	0.40	1.30	2.0	2 6
(b) Diluted	0.16	0.73	0.63	3.05	0.49	06.1	<u>2</u> 5	7.00
(15) Earning Per Share (EPS) after Exceptional Item		4	C	2 76	07.0	1 21	0 14	2.59
(a) Basic	0.10	0.45	0.02	2.76	0.48	121	0.14	2.59



1) The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at it's meeting held on 9th August 2016. These results have been reviewed by the Statutory Auditors of the company.

2) The Company is now engaged primarily in the Pharmaceutical business and there are no separate reportable segments as per AS 17.

KRLL as on 30th June, 2016 are Rs.5518.20 Lacs. The investments are of strategic and Long Term. In the opinion of the Management diminution in the value of investments is not other (3) The Company has made an investment of Rs.15490.60 Lacs to Kopran Research Laboratories Ltd (KRLL), a wholly owned subsidiary of the Company, the accumulated losses of

than temporary.

4) Other Income includes net exchange Gain of Rs.222.47 lacs during the quarter ended 30th June 2016. (Corresponding previous quarter net exchange Gain of Rs.56.55 lacs).

(5) Figures for the previous accounting period have been regrouped wherever necessary.

Place: Mumbai

Date: 09th August, 2016

**Executive Vice Chairman** ORL

KOPRAN LIMITED

KIMUMBAI THE

18

# **BATLIBOI & PUROHIT**

### **Chartered Accountants**

INDEPENDENT AUDITORS' REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

#### TO THE BOARD OF DIRECTORS OF KOPRAN LIMITED

- 1. We have reviewed the accompanying statement of unaudited financial results of **Kopran Limited** ("the Company") for the quarter ended June 30, 2016 ('the Statement'), being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015. This statement which is the responsibility of the company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25), prescribed under Section 133 of the Companies Act' 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with Accounting Standards specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 4. Without qualifying our conclusion, we draw attention to note 3 of the Statement whereby the management is of the opinion that no provision is required in respect of investment made in the subsidiary company Kopran Research Laboratories Limited for reasons stated there in.

MUMBAI TA

For BATLIBOI & PUROHIT

Chartered Accountants

Firm Reg No. 101048W

KAUSHAL MEHTA

Partner

Membership No. 111749

Place: Mumbai

Dated : August 09, 2016

## **BATLIBOI & PUROHIT**

## **Chartered Accountants**

# INDEPENDENT AUDITORS' REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

#### TO THE BOARD OF DIRECTORS OF KOPRAN LIMITED

- 1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Kopran Limited** ("the Company") and its subsidiaries (together referred to as "the Group") for the quarter ended June 30, 2016 ('the Statement'), being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulations, 2015. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Report (AS 25), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinios.
- 3. We did not review revenues and profit after tax of Rs. 3,457.32 lakhs and Rs. 62.70 lakhs respectively, included in the accompanying unaudited consolidated financial results relating to two subsidiaries, whose financial information has been reviewed by the other auditors and whose report has been furnished to us. Our conclusion on the unaudited quarterly financial results, in so far as it relates to such subsidiary is based solely on the report of the other auditors.
- 4. We did not review revenues and profit after tax of Rs. 48.36 and Rs. 0.25 lakhs respectively, included in the accompanying unaudited consolidated financial results relating to one foreign subsidiary, whose financial information has not been reviewed by other auditors and is certified by the Management.
- 5. Based on our review conducted as stated above and based on consideration of report of other auditors on the unaudited separate quarterly financial results referred to in paragraph 3 above, and based on the other financial information of the components certified by Management referred to in paragraph 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results, prepared in accordance with Accounting Standards specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

MUMBAI THE MARKET THE PARTY OF THE PARTY OF

For BATLIBOI & PUROHIT

Chartered Accountants

Firm Reg No. 101048W

KAUSHAL MEHTA

Partner

Membership No. 111749

Place: Mumbai

Dated: August 09, 2016